Ronald M. Witteles

Ronald M. Witteles

Auto-generated profile, based on publicly available information

Ronald M. Witteles

Division of Cardiovascular Medicine, Stanford Amyloid Center, Stanford University School of Medicine, Stanford, California, USA

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2008 in JACC
Verified
Journal Article
Closed access
RWRonald M. Witteles
Ronald M. Witteles
MFMichael B. Fowler
Michael B. Fowler

26 July 2022 in Circulation
Verified
Journal Article
Closed access
PDF file
HZHan Zhu
Han Zhu
FGFrancisco X. Galdos
Francisco X. Galdos
DLDaniel Lee
Daniel Lee
SWSarah Waliany
Sarah Waliany
YHYuhsin Vivian Huang
Yuhsin Vivian Huang
Sean WuSean Wu
Sean Wu
Background: Immune checkpoint inhibitors (ICIs) are monoclonal antibodies used to activate the immune system against tumor cells. Despite therapeutic benefits, ICIs have the potential to cause immune-related adverse events such as myocarditis, a rare but serious side effect with up to 50% mortality in affected patients. Histologically, patients with ICI myocarditis have lymphocytic infiltrates in the heart, implicating T cell–mediated mechanisms. However, the precise pathological immune subsets and molecular changes in ICI myocarditis are unknown. Methods: To identify immune subset(s) associated with ICI myocarditis, we performed time-of-flight mass cytometry on peripheral blood mononuclear cells from 52 individuals: 29 patients with autoimmune adverse events (immune-related adverse events) on ICI, including 8 patients with ICI myocarditis, and 23 healthy control subjects. We also used multiomics single-cell technology to immunophenotype 30 patients/control subjects using single-cell RNA sequencing, single-cell T-cell receptor sequencing, and cellular indexing of transcriptomes and epitopes by sequencing with feature barcoding for surface marker expression confirmation. To correlate between the blood and the heart, we performed single-cell RNA sequencing/T-cell receptor sequencing/cellular indexing of transcriptomes and epitopes by sequencing on MRL/Pdcd1 −/− (Murphy Roths large/programmed death-1–deficient) mice with spontaneous myocarditis. Results: Using these complementary approaches, we found an expansion of cytotoxic CD8 + T effector cells re-expressing CD45RA (Temra CD8 + cells) in patients with ICI myocarditis compared with control subjects. T-cell receptor sequencing demonstrated that these CD8 + Temra cells were clonally expanded in patients with myocarditis compared with control subjects. Transcriptomic analysis of these Temra CD8 + clones confirmed a highly activated and cytotoxic phenotype. Longitudinal study demonstrated progression of these Temra CD8 + cells into an exhausted phenotype 2 months after treatment with glucocorticoids. Differential expression analysis demonstrated elevated expression levels of proinflammatory chemokines (CCL5/CCL4/CCL4L2) in the clonally expanded Temra CD8 + cells, and ligand receptor analysis demonstrated their interactions with innate immune cells, including monocytes/macrophages, dendritic cells, and neutrophils, as well as the absence of key anti-inflammatory signals. To complement the human study, we performed single-cell RNA sequencing/T-cell receptor sequencing/cellular indexing of transcriptomes and epitopes by sequencing in Pdcd1 −/− mice with spontaneous myocarditis and found analogous expansions of cytotoxic clonal effector CD8 + cells in both blood and hearts of such mice compared with controls. Conclusions: Clonal cytotoxic Temra CD8 + cells are significantly increased in the blood of patients with ICI myocarditis, corresponding to an analogous increase in effector cytotoxic CD8 + cells in the blood/hearts of Pdcd1 −/− mice with myocarditis. These expanded effector CD8 + cells have unique transcriptional changes, including upregulation of chemokines CCL5/CCL4/CCL4L2, which may serve as attractive diagnostic/therapeutic targets for reducing life-threatening cardiac immune-related adverse events in ICI-treated patients with cancer.

1 February 2013 in JACC: Heart Failure
Verified
Journal Article
Closed access
PHPhilip S. Hall
Philip S. Hall
LHLauren C. Harshman
Lauren C. Harshman
SSSandy Srinivas
Sandy Srinivas
RWRonald M. Witteles
Ronald M. Witteles

21 April 2020 in Current Cardiology Reports
Verified
Journal Article
Open access
PDF file
HZHan Zhu
Han Zhu
JRJune-Wha Rhee
June-Wha Rhee
PCPaul Cheng
Paul Cheng
SWSarah Waliany
Sarah Waliany
ACAmy Chang
Amy Chang
Sean WuSean Wu
Sean Wu
Purpose of Review Coronavirus disease of 2019 (COVID-19) is a cause of significant morbidity and mortality worldwide. While cardiac injury has been demonstrated in critically ill COVID-19 patients, the mechanism of injury remains unclear. Here, we review our current knowledge of the biology of SARS-CoV-2 and the potential mechanisms of myocardial injury due to viral toxicities and host immune responses. Recent Findings A number of studies have reported an epidemiological association between history of cardiac disease and worsened outcome during COVID infection. Development of new onset myocardial injury during COVID-19 also increases mortality. While limited data exist, potential mechanisms of cardiac injury include direct viral entry through the angiotensin-converting enzyme 2 (ACE2) receptor and toxicity in host cells, hypoxia-related myocyte injury, and immune-mediated cytokine release syndrome. Potential treatments for reducing viral infection and excessive immune responses are also discussed. Summary COVID patients with cardiac disease history or acquire new cardiac injury are at an increased risk for in-hospital morbidity and mortality. More studies are needed to address the mechanism of cardiotoxicity and the treatments that can minimize permanent damage to the cardiovascular system.

1 January 2014 in Heart Rhythm
Verified
Journal Article
Closed access
BVBrandon C. Varr
Brandon C. Varr
SZShirin Zarafshar
Shirin Zarafshar
TCTerra Coakley
Terra Coakley
MLMichaela Liedtke
Michaela Liedtke
RLRichard A. Lafayette
Richard A. Lafayette
RWRonald M. Witteles
Ronald M. Witteles

1 November 2010 in JACC
Verified
Journal Article
Closed access
GYGeoffrey J. Yoon
Geoffrey J. Yoon
MTMelinda L. Telli
Melinda L. Telli
DKDavid P. Kao
David P. Kao
KMKelly Y. Matsuda
Kelly Y. Matsuda
RCRobert W. Carlson
Robert W. Carlson
RWRonald M. Witteles
Ronald M. Witteles